ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

Inclusion Criteria: * Patients who are planned to have percutaneous coronary intervention with exclusive use of everolimus-eluting stent (XienceTM series). * Patients with high bleeding risk defined by Academic Research Consortium or acute coronary syndrome * Patients who could take dual antiplatelet therapy with aspirin and P2Y12 inhibitors for 1-month Exclusion Criteria: * Patients who are judged to be unsuitable for participation by the principal investigator and co-investigator * Patients with a known allergy to the study drugs * Patients enrolled in the ongoing prospective interventional studies